×
About 2,730 results

ALLMedicine™ Spinocerebellar Ataxia Center

Research & Reviews  1,071 results

The progression rate of spinocerebellar ataxia type 3 varies with disease stage.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107762
Journal of Translational Medicine; Peng L, Peng Y et. al.

May 16th, 2022 - In polyglutamine (polyQ) diseases, the identification of modifiers and the construction of prediction model for progression facilitate genetic counseling, clinical management and therapeutic interventions. Data were derived from the longest longit...

Association between cortical gyrification and white matter integrity in spinocerebellar...
https://doi.org/10.1093/cercor/bhac199
Cerebral Cortex (New York, N.Y. : 1991); Tang J, Xie Y et. al.

May 15th, 2022 - Gray matter volume and thickness reductions have been reported in patients with spinocerebellar ataxia type 3 (SCA3), whereas cortical gyrification alterations of this disease remain largely unexplored. Using local gyrification index (LGI) and fra...

Expanding the landscape of Spinocerebellar Ataxia type 5 (SCA5).
https://doi.org/10.1055/a-1849-8128
Neuropediatrics Benevides ML, França M

May 12th, 2022 - Spinocerebellar ataxia type 5 (SCA5) is a rare subtype of SCA that usually affects adults. It has been recently reported in children in Europe, North America, and China. This study aims to describe clinical, radiological, and genetic data of a chi...

Clinical, Radiological, and Genetic Profile of Spinocerebellar Ataxia 12: A Hospital-Ba...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029677
Tremor and Other Hyperkinetic Movements (New York, N.Y.); Ganaraja VH, Holla VV et. al.

May 10th, 2022 - Spinocerebellar ataxia type-12 (SCA12) is a rare form of SCA, most commonly reported from the Indian Agarwal and related families. In this study we describe the clinical, genetic, and radiological characteristics of a sizeable cohort of geneticall...

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
https://clinicaltrials.gov/ct2/show/NCT03378414

May 9th, 2022 - This is a random, open label, and parallel controled experiment. 45 patients are selected and sign consent forms, then divided into three groups. Doctors collect the basic information of patient (including age,height, mental condition, vital sign,...

see more →

Clinicaltrials.gov  15 results

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
https://clinicaltrials.gov/ct2/show/NCT03378414

May 9th, 2022 - This is a random, open label, and parallel controled experiment. 45 patients are selected and sign consent forms, then divided into three groups. Doctors collect the basic information of patient (including age,height, mental condition, vital sign,...

Identification of Biomarkers in Spinocerebellar Ataxia 3
https://clinicaltrials.gov/ct2/show/NCT03885167

Feb 11th, 2022 - Participants will undergo a SARA exam, a lumbar puncture and a blood draw. A lumbar puncture is a procedure in which a small amount of the spinal fluid that surrounds the brain and spinal cord is removed by inserting a needle in the lower back. Pa...

Clinical Trial Readiness for SCA1 and SCA3
https://clinicaltrials.gov/ct2/show/NCT03487367

Jan 19th, 2022 - Spinocerebellar ataxia types 1 (SCA1) and 3 (SCA3) are rare, inherited neurodegenerative disorders that relentlessly progress to total disability and death. SCA1 is the fastest progressing SCA while SCA3 is the most common SCA in US and Europe. Ex...

Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases
https://clinicaltrials.gov/ct2/show/NCT04529252

Oct 14th, 2021 - The investigators are initiating a new program dedicated to the research and study of neurodegenerative forms of spinocerebellar ataxia as well and other nucleotide repeat diseases with the exclusion of Huntington's Disease. The analysis will be c...

Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
https://clinicaltrials.gov/ct2/show/NCT04399265

Dec 9th, 2020 - Spinocerebellar ataxia 3 (SCA3) is a rare form of inherited neurodegenerative disease involving progressive degeneration of spinocerebellar tract. SCA3 is characterised by increasingly worsening cerebellar function leading to gait abnormalities an...

see more →

News  6 results

Certifying Medical Cannabis: What APRNs Need to Know
https://www.medscape.com/viewarticle/943249

Jan 5th, 2021 - A patient asks an advanced practice registered nurse (APRN) to approve them for "medical marijuana." What are the clinician's responsibilities? The first hurdle is legal. In 18 states, an APRN has the legal authority to certify a patient to use ma...

Neurologists Review the Data on Treatments for Spinocerebellar Ataxias
https://www.mdedge.com/neurology/article/141127/movement-disorders/neurologists-review-data-treatments-spinocerebellar

Jun 23rd, 2017 - MIAMI—Advances in genetic testing have enabled precise identification of many spinocerebellar ataxias, but no pharmacologic therapy for the disorders has been approved, according to an overview presented at the First Pan American Parkinson’s Disea.

Discoveries Could Slow Dysfunction in Spinocerebellar Ataxia Type 1
https://www.mdedge.com/familymedicine/article/46776/neurology/discoveries-could-slow-dysfunction-spinocerebellar-ataxia/page/0/1
Internal Medicine News;

Dec 19th, 2011 - Dr. Cvetanovic and her associates found that the expression of the gene for VEGF, an angiogenic and neurotrophic growth factor, was downregulated in the cerebellar Purkinje neurons of SCA1 mice before they showed any behavioral or pathologic signs.

Huntington's Biomarker Discovery Could Set Tone for Trials
https://www.mdedge.com/neurology/article/48658/neuromuscular-disorders/huntingtons-biomarker-discovery-could-set-tone
Jeff Evans

Nov 1st, 2011 - A biomarker found in the blood of patients with Huntington's disease appears to mark early stages of the disease and measure response to treatment, without confusing signs of Huntington's with those of other neurodegenerative diseases. Yi Hu, Ph.

Neuroscientist Awarded Prize for Pioneering Genetics Work
https://www.medscape.com/viewarticle/750378

Sep 26th, 2011 - September 26, 2011 — Huda Y. Zoghbi, MD, professor of pediatrics, molecular and human genetics, and neurology and neuroscience at Baylor College of Medicine in Houston, Texas, has been named the recipient of the 2011 Gruber Neuroscience Prize. The...

see more →